Ouro Medicines’ drugs deplete disease-driving immune cells, allowing the immune system to reset with naïve cells that don’t attack the body. Monograph Capital founded the startup in partnership with GSK.
In a sit-down interview at the annual J.P. Morgan Healthcare conference, Allen talked about a tool built by a company backed by General Catalyst and…
Johnson & Johnson’s agreement to acquire Intra-Cellular Therapies brings Caplyta, which is projected to become a blockbuster seller across several neurological indications. In other M&A…
At JPM25, Nvidia announced four new partnerships focused on scaling AI models across the healthcare industry. The company is teaming up with Mayo Clinic, Illumina,…
There was a slight decrease in 2024 digital health venture funding compared to 2023, according to a new report from Rock Health. This partially due…
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: Alicia…
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer. This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: Matthew…
Program: State-of-the-Art Interdisciplinary Management of Prostate Cancer This series is part of an Independent Medical Education Initiative Supported by BAYER U.S. LLC PHARMACEUTICALS Biographies: Neal…
Eric Kim discusses the variation in prostate cancer genomic subtypes related to MRI PI-RADS scores and racial differences. He focused on the correlations between mpMRI…
Zachary Klaassen interviews Oliver Sartor about three significant prostate cancer trials presented at ESMO 2024. Dr. Sartor discusses the ARANOTE, PEACE-3, and the SPLASH trials.…
Health systems preparing for an M&A, or even those not immediately considering one, must prioritize a robust workforce data strategy. This approach is essential for…
